• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

¿Habla Español? | Clic Aqui

¿Habla

español?

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

263.16 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 17, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 263.16
Bid (Size) 260.01 (1)
Ask (Size) 295.40 (1)
Prev. Close 263.16
Today's Range 263.16 - 263.16
52wk Range 187.16 - 311.88
Shares Outstanding 144,000,000
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Should You Buy Biogen Before a Big July Decision?
March 19, 2023
Biogen stock has dropped about 40% from its record high. 
Via The Motley Fool
Price Over Earnings Overview: Biogen
March 17, 2023
 
Via Benzinga

Performance

YTD
-3.47%
-3.47%
1 Month
-5.47%
-5.47%
3 Month
-7.46%
-7.46%
6 Month
+25.76%
+25.76%
1 Year
+27.25%
+27.25%

More News

Read More
(BIIB) - Analyzing Biogen's Short Interest
March 17, 2023
Via Benzinga
Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year
March 16, 2023
Via Benzinga
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
March 16, 2023
Via Benzinga
Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
March 16, 2023
From Biogen Inc.
Via Globe NewsWire
Biogen's Debt Overview
March 15, 2023
Via Benzinga
1 Reason to Buy Biogen Stock, and 1 Reason to Sell
March 14, 2023
Via The Motley Fool
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode
March 15, 2023
Via FinancialNewsMedia
Exposures COVID-19
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
March 14, 2023
Via Benzinga
Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
March 14, 2023
Via MarketBeat
Exposures COVID-19
Analyst Creates Bullish Pitch For Sage Therapeutics Around Greater Enthusiasm For Its Depression Drug, Zuranolone
March 13, 2023
Via Benzinga
Reata Pharma Stock Halted After Winning 'Coin-Flip' FDA Approval
February 28, 2023
Via Investor's Business Daily
Eli Lilly's Decade-Long Effort In Alzheimer's Disease Just Failed
March 09, 2023
Via Investor's Business Daily
Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock
March 09, 2023
Via InvestorPlace
Elliott Wave Technical Analysis: Biogen Inc. - Wednesday, March 8
March 08, 2023
Via Talk Markets
Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors
March 08, 2023
From Biogen Inc.
Via Globe NewsWire
Why Shares of Anavex Life Sciences Rose 12.4% in February
March 06, 2023
Via The Motley Fool
Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment
March 06, 2023
Via Benzinga
FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
March 05, 2023
From Biogen Inc.
Via Globe NewsWire
What Does Biogen's Debt Look Like?
March 02, 2023
Via Benzinga
Peering Into Biogen's Recent Short Interest
March 01, 2023
Via Benzinga
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
February 27, 2023
From Biogen Inc.
Via Globe NewsWire
Reata Stock Plummets As Official's Exit Shakes Up FDA's Neuroscience Unit
February 27, 2023
Via Investor's Business Daily
Why Reata Pharmaceuticals Shares Are Falling Monday?
February 27, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap